Obstrüktif uyku apne sendomunda serum pr-BNP düzyeleri, ventrikül fonksiyobnlari ve kardiyovasküler sonuçlar

OSAS is an important sleep disorder with many systemic effects, which is frequently seen in society. The most significant complications occur in the cardiovascular system, varying from hypertension to sudden death in sleep. Thus, getting an early diagnosis in patients with OSAS, and treatment will abate the mortality and morbidity. It will also be possible to protect these patients from the cardiovascular mortality and morbidity of OSAS at early stages if any parameters that show the risk of cardiovascular disease can be found. Therefore, a great deal of research has been conducted on the effects of OSAS on cardiovascular system, and on the laboratory methods that will determine those effects.In the present study, pro-BNP levels, a biochemical parameter used in cardiovascular diseases, are measured in OSAS and control groups, and whether it contributes to determining the risk of emergence of cardiovascular disease has been examined. A total of 55 patients examined with OSAS doubt participated in the study,which was conducted between November 2009-February 2010 at Gazi University Faculty of Medicine Department of Pulmonary Medicine Sleep Disorders Center. PSG was applied to all the patients. Based on the PSG results, 30 cases were diagnosed as OSAS and included in the patient group; and 25 cases, which are not diagnosed as OSAS, were included in the control group. In the morning of PSG application, pro-BNP levels of all the cases were measured. The pro-BNP levels of patients in OSAS group were measured again after a 4-week CPAP treatment. Measurements have revealed that pro-BNP levels have increased in OSAS group when compared to the control groups. At the same time, whenpro-BNP levels before and after CPAP treatment are compared to each other in OSAS group, it has been found that pro-BNP levels have decreased after treatment.Based on these results; pro-BNP can be used as an early indicator of cardiovascular disfunction in OSAS cases without any heart disease so that the risk management could be handled before the clinic, mortality and morbidity of cardiovascular disease arises in these patients.Key Words: OSAS, pro-BNP, Cardiovascular disfunction.